CONCENTRATIONS AND UNCERTAINTIES |
9 Months Ended |
|---|---|
May 31, 2026 | |
| Risks and Uncertainties [Abstract] | |
| CONCENTRATIONS AND UNCERTAINTIES | CONCENTRATIONS AND UNCERTAINTIES Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. The Company holds cash and cash equivalents with balances that exceed FDIC-insured limits. Cash maintained in excess of these limits is on deposit with a large, national bank. Accordingly, the Company does not have depository exposure to regional banks. In addition, the Company holds cash at a bank in France that is not FDIC-insured. Historically, the Company has not experienced any losses in such accounts, and management believes that the financial institutions at which its cash is held are stable; however, no assurances can be provided. Revenue concentration shows that international sales accounted for 29% and 27% of revenue for the nine months ended May 31, 2026, and May 31, 2025, respectively. Our three largest customers in terms of revenue accounted for 7%, 4%, and 4% of total revenues, respectively, for the nine months ended May 31, 2026. Our three largest customers in terms of revenue accounted for 7%, 4%, and 3% of total revenues, respectively, for the nine months ended May 31, 2025. Accounts receivable concentrations show that our three largest customers in terms of accounts receivable each comprised between 4% and 12% of accounts receivable as of May 31, 2026; our three largest customers in terms of accounts receivable comprised between 5% and 12% of accounts receivable as of May 31, 2025. As of the filing date of this report, a substantial majority of the outstanding receivable balance from our largest customer, which represented 12% of accounts receivable as of May 31, 2026, was current on all outstanding invoices, except for a de minimis amount. We operate in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.
|